Literature DB >> 14595755

Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R).

Kresimir Pavelić1, Toni Kolak, Sanja Kapitanović, Senka Radosević, Sime Spaventi, Bozo Kruslin, Jasminka Pavelić.   

Abstract

Insulin-like growth factor 2 (IGF 2) appears to be involved in the progression of many tumours. It binds to at least two different types of receptor: IGF type 1 (IGF 1R) and mannose 6-phosphate/IGF type 2 (M6-P/IGF 2R). Ligand binding to IGF 1R provokes mitogenic and anti-apoptotic effects. M6-P/IGF 2R has a tumour suppressor function--it mediates IGF 2 degradation. Mutation of M6-P/IGF 2R causes both diminished growth suppression and augmented growth stimulation. The aim of this study was to investigate the role of IGF 2 and its receptors (IGF 1R and IGF 2R) in human gastric cancer. The expression of IGF 2 and its receptors was measured in order to analyse the possible correlation between the activity of these genes and cell proliferation in two different gastric tumour types: diffuse and intestinal. The effect of IGF 1 receptor blockage on cell proliferation and anchorage-independent cell growth was also examined. Increased expression of IGF 2 and IGF 1R genes (at the mRNA and protein level) was found in gastric cancer when compared with non-tumour tissue. Furthermore, there was a significant difference between IGF 2 expression in the more aggressive diffuse type and that in the intestinal type of gastric cancer. Moreover, the IGF 2 peptide level in the culture media obtained from the diffuse type of cancer cells was significantly higher when compared with the intestinal type. The level of IGF 2 peptide in the conditioned media strongly correlated with [3H]thymidine incorporation and cell proliferation. On the contrary, IGF 2R mRNA expression was much higher in the intestinal type of cancer than in the diffuse type. In addition, IGF 2R protein expression was substantially lower with progression of the diffuse cancer type to a higher stage. The alphaIR3 monoclonal antibody strongly inhibited [3H]thymidine incorporation and decreased the number of colonies in soft agar of cells overexpressing IGF 2. These findings suggest that members of the IGF family are involved in the pathogenesis of gastric cancer, probably by autocrine/paracrine stimulation of cell growth. Such tumours might be excellent candidates for therapeutic strategies aimed at interference with this pathway. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595755     DOI: 10.1002/path.1465

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  22 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

2.  Association between IRS-2 G1057D polymorphism and risk of gastric cancer.

Authors:  Xiao-Mei Zhao; Jie Chen; Li Yang; Xuan Luo; Lin-Lin Xu; Dong-Xiao Liu; Su-Lan Zhai; Ping Li; Xue-Rong Wang
Journal:  World J Gastrointest Oncol       Date:  2012-01-15

3.  Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.

Authors:  Y Min; Y Adachi; H Yamamoto; A Imsumran; Y Arimura; T Endo; Y Hinoda; C-T Lee; S Nadaf; D P Carbone; K Imai
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

4.  Expression of some tumor associated factors in human carcinogenesis and development of gastric carcinoma.

Authors:  Ming-Dong Zhao; Xue-Mei Hu; Dian-Jing Sun; Qun Zhang; Yu-Hao Zhang; Wei Meng
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers.

Authors:  Yasushi Adachi; Hiroyuki Yamamoto; Hirokazu Ohashi; Takao Endo; David-P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

Review 6.  Diabetes and gastric cancer: the potential links.

Authors:  Chin-Hsiao Tseng; Farn-Hsuan Tseng
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis.

Authors:  Jae Moon Yoon; Ki Young Son; Chun Sick Eom; Daniel Durrance; Sang Min Park
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

8.  Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.

Authors:  Koji Numata; Takashi Oshima; Kentaro Sakamaki; Kazue Yoshihara; Toru Aoyama; Tsutomu Hayashi; Takanobu Yamada; Tsutomu Sato; Haruhiko Cho; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Chikara Kunisaki; Makoto Akaike; Toshio Imada; Munetaka Masuda
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-03       Impact factor: 4.553

9.  Association of gastric cancer with tyrosine hydroxylase gene polymorphism in a northwestern Chinese population.

Authors:  Z Q Li; W P Yu; X D Xie; P Q Li; T K Guo; W H Zhang; L Z An; X L Wang
Journal:  Clin Exp Med       Date:  2007-10-03       Impact factor: 3.984

10.  Physical activity and esophageal and gastric carcinoma in a large prospective study.

Authors:  Michael F Leitzmann; Corinna Koebnick; Neal D Freedman; Yikyung Park; Rachel Ballard-Barbash; Albert Hollenbeck; Arthur Schatzkin; Christian C Abnet
Journal:  Am J Prev Med       Date:  2008-12-05       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.